Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR111 in advanced malignancies
NCT06937957Phase 1Recruiting
- Sponsor
- BioRay Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BR111 in malignant neoplasms (advanced stage), solid tumor (advanced stage) and B cell lymphoma, sponsored by BioRay Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 9 months and Recommended Phase 2 Dose at 9 months. Started Apr 2025; status: recruiting.
02
Drugs
BR111
03
Conditions
malignant neoplasms (advanced stage)solid tumor (advanced stage)B cell lymphoma
Beyond the preview
Go deeper on NCT06937957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937957.